Larimar Therapeutics Inc (LRMR) - News Archive

Friedreich s Ataxia (FA) remains a challenging rare neurological disease characterized by progressive ataxia, loss of reflexes, and scoliosis, primarily resulting from the deficiency of the protein frataxin. Recent repo...

Larimar Therapeutics, Inc. a clinical-stage biotechnology company dedicated to developing therapies for complex rare diseases, recently presented additional data from its nomlabofusp clinical program during the Internat...

BALA CYNWYD, Pa., May 30, 2024 - Leading biotechnology company Larimar Therapeutics, Inc. (Nasdaq: LRMR) proudly announces its selection by the United States Food and Drug Administration (FDA) to participate in the pion...

Larimar Therapeutics, a clinical-stage biotechnology company, has recently announced a significant milestone in the development of its novel treatment, nomlabofusp (CTI-1601), for Friedreich s Ataxia (FA). The U.S. Food...

Friedreich s ataxia (FA) is a debilitating, progressive, and rare neurological disorder that primarily affects the nervous system and muscles. It is caused by a genetic mutation that leads to reduced levels of frataxin,...

BALA CYNWYD, Pa., Feb. 16, 2024 - Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a leading biotechnology company specializing in the development of treatments for rare diseases, has successfully completed its unde...

Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common StockBALA CYNWYD, Pa., Feb. 14, 2024 - Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused...

Larimar Therapeutics Proposed Underwritten Public Offering and its ImplicationsLarimar Therapeutics, a clinical-stage biotechnology company specializing in developing treatments for complex rare diseases, recently made...

Larimar Therapeutics Promising Phase 2 Study Indicates Potential Breakthrough in Friedreich s Ataxia TreatmentBALA CYNWYD, Pa. - Larimar Therapeutics, a clinical-stage biotechnology company focused on developing treatme...